Objective: This study was performed to define the incidence of acute deep venous thrombosis (DVT) after endovascular treatment of abdominal aortic aneurysms (AAAs). Because aortic endograft placement requires prolonged femoral vessel instrumentation, it may be hypothesized that these patients are at increased risk for development of an acute DVT. Deep venous thrombosis (DVT) and pulmonary embolism (PE) are serious complications that affect the hospitalized patient. Recent investigations place the incidence rate of DVT and PE between 69 and 139 cases per 100,000 people in the general population, with a prevalence of 350 cases per 100,000 hospital admissions.
Deep venous thrombosis (DVT) and pulmonary embolism (PE) are serious complications that affect the hospitalized patient. Recent investigations place the incidence rate of DVT and PE between 69 and 139 cases per 100,000 people in the general population, with a prevalence of 350 cases per 100,000 hospital admissions. [1] [2] [3] Autopsy data suggest that this disease process accounts for approximately 235,000 deaths annually. 1 In one series, almost one quarter of the in-hospital PEs occurred in postoperative patients. 4 Factors that place patients at increased risk for development of PE include hypercoagulability, blood flow stasis, and endothelial cell damage. It is likely that the latter two processes underlie the increased risk of DVT and PE in most surgical patients. Several series have shown venous stasis and vein lumen dilatation, thought to subsequently cause endothelial cell damage, during operative procedures. [5] [6] [7] Coleridge-Smith, Hat, and Scurr 7 showed, with ultrasound scan examination, that venous distension occurred during the conduction of the operative procedure and not at the induction of anesthesia. Clearly, patients needing major surgical procedures are at increased risk of DVT and PE. Pooled data from control arms of DVT prophylaxis trials estimate the incidence rate of DVT in the general surgery population to be approximately 25% in untreated subjects, and this incidence rate rises to 65% in those undergoing elective orthopedic surgery. 8 With the institution of routine pharmacologic and mechanical DVT prophylaxis, these rates have been reduced three-fold. 9, 10 The risk of DVT and PE in the vascular surgery population has not been well studied. Recent literature suggests that the incidence rate of DVT after peripheral vascular surgery varies widely from 2% to 32%. [11] [12] [13] [14] [15] With the advent of endovascular repair of abdominal aortic aneurysms (AAAs), a subset of patients not previously eligible for open operative repair may be undergoing operative intervention. These patients may be at increased risk for the development of DVT compared with those undergoing conventional open repair. These more elderly patients with more comorbidities are more likely to be sedentary than those undergoing open procedures. The incidence rate of malignant disease in this population has been reported as high as 12%. 16 Prolonged device manipulation within the femoral and iliac arteries may result in trauma to the adjacent veins, injure the endothelium, and incite DVT formation. Despite these factors, DVT and PE complicating endovascular AAA repair has been recognized in only 1% to 2% of patients. 16, 17 The aim of this study was to evaluate the incidence of acute DVT and risk factors for DVT after endovascular AAA repair.
PATIENTS AND METHODS
Fifty consecutive patients who underwent endovascular treatment of an AAA between January 2000 and August 2001 at the University of Michigan Hospital were studied prospectively. Included were 42 men and eight women, ranging in age from 48 to 85 years (mean, 72 Ϯ 1 years). Comorbidities included patient demographics, history of cancer, prior DVT, and history of hypercoagulable states. Intraoperative data, in-cluding graft type, mode of anesthesia, operative time, estimated blood loss, volume and type of blood product transfused, dose of heparin, and the dose of protamine administered were analyzed. Utilization of perioperative anticoagulation therapy was also examined. The University of Michigan Internal Review Board (#2001-773) approved this study.
In all patients, bilateral lower extremity duplex ultrasonography for acute DVT was performed on the first postoperative day and at the first follow-up visit (within 4 weeks after discharge) according to an established protocol for endovascular aortic aneurysm repairs. Duplex ultrasonography was performed with a high-resolution real-time imager and integrated, pulsed, range-gated Doppler with color flow imaging with a 5-MHz to 7.5-MHz transducer. The posterior tibial, anterior tibial, peroneal, popliteal, femoral, common femoral, and external iliac veins were assessed. Acute thrombus was considered present when echolucent intravenous material hindering vein wall compression was noted in conjunction with a dilated vein and lack of wellformed collaterals. Absence of augmented signals with respiration and a lack of vessel filling with color mode were also suggestive of acute DVT. 18 All examinations were performed by licensed or registered vascular technologists and reviewed by board certified vascular surgeons in an Intersocietal Commission for the Accreditation of Vascular Laboratories-accredited laboratory. The University of Michigan Diagnositc Vascular Unit images entire lower extremity DVTs with duplex ultrasonography with a sensitivity of 96%, a specificity of 90%, and an accuracy of 95%. For the diagnosis of calf vein DVT, the sensitivity, specificity, and accuracy are reduced to 82%, 77%, and 80%, respectively.
Data are expressed as the mean Ϯ the standard error of the mean unless otherwise stated. Risk factors for DVT were evaluated with 2 analysis for nominal data and the Wilcoxan rank-sum test for continuous data. All statistical analyses were performed with StatView Version 4.5 (Abacus Concepts, Inc, Berkely, Calif).
RESULTS
None of the 50 patients had a prior DVT or identifiable hypercoagulable state. However, seven patients (14%) had concurrent malignant disease that included: metastatic Merckel cell carcinoma (n ϭ 1), esophageal cancer (n ϭ 1), cutaneous basal cell carcinoma (n ϭ 1), renal cell carcinoma (n ϭ 1), and prostate cancer (n ϭ 3). The characteristics of the patients in this series were typical of individuals with AAAs (Table I) .
Before surgery, 26 patients (52%) were receiving antiplatelet agents and nine (18%) were on warfarin sodium therapy (six for atrial fibrillation, two for severe ventricular dysfunction, and one for a mechanical heart valve). Antiplatelet agents were continued perioperatively. Patients receiving warfarin sodium therapy had this medication discontinued 4 days before surgery. They were started on subcutaneous low-molecular weight heparin after surgery and were continued on this drug until their international normalized ratio was above 2.0. No new DVT prophylaxis was initiated perioperatively to this series' patients.
Two patients who underwent AAA repair had contained aortic ruptures, and one patient was symptomatic with back pain but no evidence of rupture on computed tomographic scan. Eight AAAs were less than 5 cm in diameter. Two of these aneurysms had concurrent 4-cm and 5-cm iliac artery aneurysms. One of these less than 5-cm aneurysms presented as a contained rupture, and another was symptomatic. Three of these aneurysms had a greater than 0.5-cm increase in anteroposterior diameter over a period of 6 months. The last patient with a less than 5-cm AAA had a discrete sacular aneurysm, suggesting an advanced degenerative process affecting a focal area of the aorta.
Operative data were revealing (Table II) . Twenty-two percent of the patients did not receive protamine. One patient was converted to open repair because of intraoperative rupture of the external iliac artery. Complications included one patient needing an iliofemoral thrombectomy in the immediate postoperative period because of a common femoral artery dissection. One patient had a postoperative myocardial infarction and had acute renal failure develop. This patient did not need acute dialysis. Ambulation occurred, on average, on postoperative day 2 Ϯ 0.3 (range, 1 to 9 days; median, 1 day). There were no perioperative deaths, and median hospital stay was 2 days (range, 1 to 18 days). Follow-up for all patients averaged 8 Ϯ 0.8 months (range, 1 to 18 months). Three patients (6%) had an acute DVT develop after surgery, two affecting the femoral veins and one affecting the popliteal vein (Table III ). All these patients had received 5000 units of heparin during surgery, and all underwent reversal with protamine. In the first patient, an acute DVT was observed affecting the left popliteal vein with duplex ultrasonography on the first postoperative day. The patient was asymptomatic. The second patient had previous arterial surgery necessitating a femoral artery dissection, and during the dissection for the endovascular graft device placement, the femoral vein was injured. This patient had pain and swelling on the affected side on the first postoperative day. A duplex ultrasound scan revealed an acute DVT in the common femoral vein. The third patient had initial duplex ultrasonographic examinations that revealed no evidence of DVT. The individual had metastatic Merckel cell carcinoma and was begun on chemotherapy, including paclitaxel and carboplatin 1 week after surgery. The patient was seen for follow-up 1 month after aneurysm repair with unilateral leg swelling and pain. Duplex ultrasonography revealed an acute right midfemoral DVT. No identified factors placed these patients at significantly greater risk for the development of acute DVT compared to those without DVT. No patient with DVT had evidence of PE. Two of the patients had no long-term sequelae from their DVT or anticoagulation therapy. One patient had gastrointestinal bleeding develop from gastritis and had the warfarin sodium therapy discontinued after 4 months of treatment. There were no mortalities among the 50 patients studied.
DISCUSSION
The risk of perioperative DVT formation after conventional aortic surgery remains ill defined. Early studies with 125 I-labeled fibrinogen with or without a second modality placed the risk for DVT formation between 1.5% and 40% after aortic surgery. [19] [20] [21] [22] The use of labeled fibrinogen, however, is inaccurate and has been abandoned because it is poor at detecting proximal thigh and pelvic thrombus and there was a high incidence rate of false-positives study results. 20 Venography, once the gold standard for DVT diagnosis, was used in one study to assess the incidence of DVT formation after aortic surgery, with a reported incidence rate of 18%. 12 All of the patients in the latter study were asymptomatic, and 78% had the DVT limited to a calf vein. On the basis of the data from the latter study, Olin et al 12 recommended that patients undergoing conventional aortic surgery may benefit from DVT prophylaxis.
More recently, duplex ultrasonography has been used to diagnose DVT in several studies of patients undergoing open aortic surgery. With this method, the reported incidence rate of DVT formation after traditional open AAA repair still varies widely, ranging from 2% to 41%. [13] [14] [15] 23 Hollyoak et al 15 recently studied the incidence of DVT after major vascular surgical procedures without routine DVT prophylaxis and reported a 41% incidence rate of DVT after open aortic surgery. Similar to the report of Olin et al, 12 most of these DVTs (80%) were confined to the calf veins. Fletcher and Batiste 14 documented the incidence rate of DVT after aortic surgery to be 11.5% despite DVT prophylaxis with unfractionated heparin. Farkas and colleagues, 23 however, noted a lessening of DVT from 10.6% to 4.2% with prophylaxis with low-molecular weight heparin compared with unfractionated heparin. Killewich et al 13 showed no difference in the incidence rate of DVT between patients receiving DVT prophylaxis with unfractionated heparin (2%) compared with those not given DVT prophylaxis (2%).
This study represents a group of patients undergoing AAA repair with an endovascular approach. Before this report, there has been no clear documentation as to the risk of DVT after endovascular AAA repair. One could argue that shortened hospital stays and earlier return to daily activities should reduce the risk of DVT formation. However, given that most DVTs in surgical patients develop during the time of the operation, the risk in this group may not necessarily be lower. Furthermore, one could speculate that prolonged instrumentation of the femoral vessels may lead to an increased risk of DVT formation. Although none of these patients had a history of hypercoaguable state, two patients were operated on for aortic rupture and a third patient for suspected rupture. Bradbury and colleagues 24 suggest that there is a hypercoaguable state associated with ruptured aortic aneurysms. Forty percent of the patients in that series had thrombocytosis develop, and these patients were at higher risk for development of a DVT. Although none of the ruptured aneurysms in this series had a DVT develop, none had postoperative thrombocytosis develop. It will be interesting, as more ruptured aneurysms are repaired in an endovascular fashion, to evaluate whether these patients have physiologic problems develop similar to those undergoing conventional ruptured AAA repair. The 6% incidence rate of DVT in this study appears to be consistent with the incidence rate reported in earlier studies after conventional AAA repair. Endovascular AAA repair appears to carry no increased or decreased risk of DVT. It may be important to note that there were no calf vein DVTs documented in this group of patients for endovascular treatment. This is contrary to the reported experience with open aortic surgery, in which upwards to 80% of diagnosed DVTs were in the calf veins. Olin et al 12 used venography to diagnose DVT, and thus their study likely had a higher sensitivity and specificity in diagnosing calf vein DVT compared with this series and may explain some of the difference. Hollyoak et al, 15 however, used duplex ultrasonagraphy and continued to have a higher incidence rate of calf vein DVT. The sensitivity and specificity of duplex ultrasonography in that series was not reported. No risk factors placed our patients at increased risk for development of acute DVT. In fact, it is likely that the one patient with metastatic Merkel cell carcinoma had a DVT develop independent of the endovascular AAA repair. The patient's initial duplex scan examinations were negative for DVT on two occasions, and the patient did not present until 1 months after surgery soon after beginning chemotherapy for the neoplasm.
The small number of patients who underwent endovascular AAA repair and the small number in whom DVT developed in this study limit the statistical power to accurately identify risk factors for DVT. Assuming a comparison of two equal groups and a baseline event rate of 6%, approximately 1600 patients would be required to detect a 50% relative reduction and 7200 patients to detect a 25% relative reduction for a power of 80% with a two-sided ␣ of 0.05. Thus the limitation of studying only 50 patients is clearly understood.
On the basis of this current review, and on most previous studies, no firm recommendation can be made with regard to DVT prophylaxis during aortic surgery, whether open or endovascular. One could argue that because most DVTs in surgical patients develop during the operative procedures 25 and because most vascular surgery patients receive intravenous heparin therapy during the operation, that they are already afforded DVT prophylaxis. Certainly, those patients already on anticoagulation therapy should continue it perioperatively, provided it is not medically contraindicated, and those patients with recognized risk factors for the development of DVT (separate from surgery) may benefit from prophylaxis. However, there is no justification that patients undergoing endovascular AAA repair require DVT screening or prophylaxis. In The responsible author (Dr Olivier Goëau-Brissonnière) did not state the following competitive interests in regard to the above paper.
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